BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 26933124)

  • 21. First-line gefitinib treatment in elderly patients (aged ≥75 years) with non-small cell lung cancer harboring EGFR mutations.
    Kuwako T; Imai H; Masuda T; Miura Y; Seki K; Yoshino R; Kaira K; Utsugi M; Shimizu K; Sunaga N; Tomizawa Y; Ishihara S; Ishizuka T; Mogi A; Hisada T; Minato K; Takise A; Saito R; Yamada M
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):761-9. PubMed ID: 26254024
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients.
    Roengvoraphoj M; Tsongalis GJ; Dragnev KH; Rigas JR
    Cancer Treat Rev; 2013 Dec; 39(8):839-50. PubMed ID: 23768755
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC.
    Riess JW; Gandara DR; Frampton GM; Madison R; Peled N; Bufill JA; Dy GK; Ou SI; Stephens PJ; McPherson JD; Lara PN; Burich RA; Ross JS; Miller VA; Ali SM; Mack PC; Schrock AB
    J Thorac Oncol; 2018 Oct; 13(10):1560-1568. PubMed ID: 29981927
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Uncommon EGFR mutations in advanced non-small cell lung cancer.
    O'Kane GM; Bradbury PA; Feld R; Leighl NB; Liu G; Pisters KM; Kamel-Reid S; Tsao MS; Shepherd FA
    Lung Cancer; 2017 Jul; 109():137-144. PubMed ID: 28577943
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?
    Ou SH; Soo RA
    Drug Des Devel Ther; 2015; 9():5641-53. PubMed ID: 26508839
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations.
    Rosell R; Molina MA; Costa C; Simonetti S; Gimenez-Capitan A; Bertran-Alamillo J; Mayo C; Moran T; Mendez P; Cardenal F; Isla D; Provencio M; Cobo M; Insa A; Garcia-Campelo R; Reguart N; Majem M; Viteri S; Carcereny E; Porta R; Massuti B; Queralt C; de Aguirre I; Sanchez JM; Sanchez-Ronco M; Mate JL; Ariza A; Benlloch S; Sanchez JJ; Bivona TG; Sawyers CL; Taron M
    Clin Cancer Res; 2011 Mar; 17(5):1160-8. PubMed ID: 21233402
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor: a meta-analysis.
    Lee JK; Hahn S; Kim DW; Suh KJ; Keam B; Kim TM; Lee SH; Heo DS
    JAMA; 2014 Apr; 311(14):1430-7. PubMed ID: 24715074
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Continuation of epidermal growth factor receptor tyrosine kinase inhibitor treatment prolongs disease control in non-small-cell lung cancers with acquired resistance to EGFR tyrosine kinase inhibitors.
    Chen Q; Quan Q; Ding L; Hong X; Zhou N; Liang Y; Wu H
    Oncotarget; 2015 Sep; 6(28):24904-11. PubMed ID: 26172562
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients.
    Kuiper JL; Heideman DA; Thunnissen E; Paul MA; van Wijk AW; Postmus PE; Smit EF
    Lung Cancer; 2014 Jul; 85(1):19-24. PubMed ID: 24768581
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical Impact of Post-Progression Survival on Overall Survival in Elderly Patients with Non-Small-Cell Lung Cancer Harboring Sensitive EGFR Mutations Treated with First-Line EGFR Tyrosine Kinase Inhibitors.
    Imai H; Yamada Y; Sugiyama T; Minemura H; Kaira K; Kanazawa K; Kasai T; Kaburagi T; Minato K;
    Chemotherapy; 2018; 63(3):181-189. PubMed ID: 30107372
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Whose Tumors Harbor Uncommon EGFR Mutations.
    Klughammer B; Brugger W; Cappuzzo F; Ciuleanu T; Mok T; Reck M; Tan EH; Delmar P; Klingelschmitt G; Yin AY; Spleiss O; Wu L; Shames DS
    J Thorac Oncol; 2016 Apr; 11(4):545-55. PubMed ID: 26773740
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A diagnostic algorithm using EGFR mutation-specific antibodies for rapid response EGFR-TKI treatment in patients with non-small cell lung cancer.
    Kawahara A; Taira T; Azuma K; Tominaga M; Hattori S; Kawahara M; Abe H; Yamaguchi T; Akiba J; Takamori S; Hayashi A; Kage M
    Lung Cancer; 2012 Oct; 78(1):39-44. PubMed ID: 22858448
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation.
    Park SJ; Kim HT; Lee DH; Kim KP; Kim SW; Suh C; Lee JS
    Lung Cancer; 2012 Sep; 77(3):556-60. PubMed ID: 22677429
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advanced non-Small cell lung cancer patients at the extremes of age in the era of epidermal growth factor receptor tyrosine kinase inhibitors.
    Chen YM; Lai CH; Rau KM; Huang CH; Chang HC; Chao TY; Tseng CC; Fang WF; Chen YC; Chung YH; Wang YH; Su MC; Huang KT; Liu SF; Chen HC; Chang YC; Chang YP; Wang CC; Lin MC
    Lung Cancer; 2016 Aug; 98():99-105. PubMed ID: 27393514
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC).
    Goto K; Nishio M; Yamamoto N; Chikamori K; Hida T; Maemondo M; Katakami N; Kozuki T; Yoshioka H; Seto T; Fukuyama T; Tamura T
    Lung Cancer; 2013 Oct; 82(1):109-14. PubMed ID: 23910906
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Next-generation sequencing of tyrosine kinase inhibitor-resistant non-small-cell lung cancers in patients harboring epidermal growth factor-activating mutations.
    Masago K; Fujita S; Muraki M; Hata A; Okuda C; Otsuka K; Kaji R; Takeshita J; Kato R; Katakami N; Hirata Y
    BMC Cancer; 2015 Nov; 15():908. PubMed ID: 26572169
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low plasma concentration of gefitinib in patients with EGFR exon 21 L858R point mutations shortens progression-free survival.
    Okuda Y; Sato K; Sudo K; Hasegawa Y; Asano M; Miura H; Takeda M; Sano M; Watanabe H; Kobayashi H; Niioka T; Miura M; Ito H
    Cancer Chemother Pharmacol; 2017 May; 79(5):1013-1020. PubMed ID: 28391354
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer.
    Sacher AG; Paweletz C; Dahlberg SE; Alden RS; O'Connell A; Feeney N; Mach SL; Jänne PA; Oxnard GR
    JAMA Oncol; 2016 Aug; 2(8):1014-22. PubMed ID: 27055085
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Utilization of Molecular Testing and Survival Outcomes of Treatment with First- or Second-line Tyrosine Kinase Inhibitors in Advanced Non-small Cell Lung Cancer in a Dutch Population.
    Sluga R; VAN DEN Borne BEEM; Roepman P; Peters BJM; Kastelijn EA; Schramel FMNH
    Anticancer Res; 2018 Jan; 38(1):393-400. PubMed ID: 29277800
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of the molecular footprint of EGFR in tailoring treatment decisions in NSCLC.
    Gately K; O'Flaherty J; Cappuzzo F; Pirker R; Kerr K; O'Byrne K
    J Clin Pathol; 2012 Jan; 65(1):1-7. PubMed ID: 22039281
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.